Loading
institutionsInstitution
Hospital Clínic de Barcelona / IDIBAPS
Barcelona's university hospital, home of the BCLC liver cancer staging system, the first European academic CAR-T and leading breast and lymphoma genomics.
Also called: Hospital ClínicIDIBAPSClínic Barcelona Comprehensive Cancer Center
Overview
Hospital Clínic and its research institute IDIBAPS form one of Spain's strongest academic medical centres. The Barcelona Clinic Liver Cancer group of Jordi Bruix and Josep Maria Llovet created the BCLC staging and treatment algorithm and led the SHARP trial that made sorafenib the first systemic therapy for hepatocellular carcinoma. Elías Campo's group mapped the genome of chronic lymphocytic leukaemia within the ICGC and co-edits the WHO haematolymphoid classification, Aleix Prat's group advanced intrinsic subtyping (PAM50, HER2DX) in breast cancer, and the hospital's ARI-0001 CD19 CAR-T, developed by Manel Juan and Álvaro Urbano-Ispizua, became the first academic CAR-T authorised in Europe under Spain's hospital exemption in 2021. The centre is OECI-accredited and runs a large early-phase and haematology programme.
Location
Barcelona, ES
Type
hospital · Universitat de Barcelona
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#84 · 42 points (0 Newsweek + 0 NCI + 42 from 21 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to Hospital Clínic de Barcelona, including child institutions. 1,265 works · 15,631 citations · 68% open access · 14% clinical trials · 2% reviews.
Oncology works per year
2582022
2322023
3062024
2692025
2002026
Most works
- Susana Puig94 works
- Aleix Prat91 works
- Manel Juan81 works
- Josep Malvehy78 works
- Ana Arance58 works
- Carlos Fernández de Larrea55 works
- Álvaro Urbano-Ispizúa50 works
- Núria Martínez‐Cibrián48 works
- Julio Delgado47 works
- Cristina Carrera47 works
Most cited
- BCLC liver cancer group
- Academic CAR-T (ARI-0001, ARI-0002h)
- Lymphoid neoplasm genomics
- Breast cancer intrinsic subtypes
- Early-phase trials
Aleix Prat
Head of Medical Oncology, Hospital Clínic de Barcelona; Scientific Director, SOLTI
Breast cancer genomicsHER2-positive de-escalationPAM50 and HER2DX
Translational oncologist who built genomic tests (HER2DX) to decide which HER2-positive patients can skip chemotherapy.
Jordi Bruix
Hepatologist, Barcelona Clinic Liver Cancer group, Hospital Clínic de Barcelona
Hepatocellular carcinomaBCLC stagingSystemic therapy trials
Barcelona liver specialist who co-created the BCLC staging system used worldwide to decide how liver cancer is treated, and led STORM, which showed adjuvant sorafenib does not help after curative treatment.
Josep M. Llovet
Director, Liver Cancer Program, Icahn School of Medicine at Mount Sinai; Professor, University of Barcelona
Hepatocellular carcinomaTargeted therapyStaging systems
Led SHARP, which made sorafenib the first systemic therapy for liver cancer, and created the BCLC staging system.
Josep Maria Campistol
Chief Executive Officer
Hospital managementNephrology and transplantationAcademic medicine
Nephrologist and CEO of Hospital Clínic de Barcelona, one of Spain's leading academic hospitals.
Susana Puig
Director, IDIBAPS
MelanomaDermato-oncologyCancer genetics
Dermatologist and melanoma researcher who directs IDIBAPS, the research institute of Hospital Clínic de Barcelona.
Similar pages
- CompanySOLTI Cancer Research Group
Shares Aleix Prat, PAM50 / intrinsic subtypes, Vall d'Hebron University Hospital / VHIO, RNA sequencing & expression profiling.
- IdeaPlan the second CAR-T target before the first one is lost
Shares BCMA, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
- IdeaHospital-made CAR-T under one shared regulatory master file
Shares BCMA, Manufacturing cost and time for living and radioactive medicines, CD19, Prices and value.
- TermB cell
Shares BCMA, CD19, Chronic lymphocytic leukaemia, CAR-T cell therapy.
- PersonPolina Stepensky
Shares BCMA, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
- IdeaNon-profit, open-licence lentiviral vectors and producer cell lines for CAR-T
Shares BCMA, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
- InstitutionHadassah Medical Center
Shares BCMA, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
- PersonZelig Eshhar
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.